Arca
Skip to content

Herpes simplex

Drug research and approvals for herpes simplex: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 56 studies of herpes simplex are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, and FDA has 1 approved and 3 open orphan designations naming it.

  • Recruiting worldwide: 56
  • Trials authorized in Canada: 1
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 56 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

4 approved, 5 in phase 3, 6 in phase 2, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Acyclovir, Dexamethasone phosphoric acid, Dexamethasone, Trifluridine

Valacyclovir
Phase 3 Human herpesvirus 1 DNA polymerase inhibitor
Foscarnet
Phase 3 Human herpesvirus 1 DNA polymerase inhibitor
Famciclovir
Phase 3 Human herpesvirus 1 DNA polymerase inhibitor
Amenamevir
Phase 3 Helicase primate complex inhibitor
Vidarabine
Phase 3 Human herpesvirus 1 DNA polymerase inhibitor
Docosanol
Phase 2 Envelope glycoprotein inhibitor
Glutamine
Phase 2 Unknown
Glycine
Phase 2
QS-21
Phase 2
Cidofovir anhydrous
Phase 1 Human herpesvirus 1 DNA polymerase inhibitor
Aspirin
Phase 1 Cyclooxygenase inhibitor
Pritelivir
Phase 1 Helicase/primase inhibitor

How Its Trials Ended

316 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 89 whose ending is known, 61% met their primary endpoint, 11% missed it and 28% stopped early.

  • Completed, result not reported15248%
  • Met its primary endpoint5417%
  • Ongoing4615%
  • Status unknown299%
  • Stopped: other or unclear113%
  • Missed its primary endpoint103%
  • Stopped: enrollment or feasibility62%
  • Stopped: sponsor or business decision52%
  • Stopped: lack of efficacy31%

Trials Authorized in Canada

Newest first; search them all in Canada trials
AuthorizedTrialSponsorStatus
Aug 31, 2022A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of…Pritelivir / probenecidAiCuris Anti-Infective CuresClosed

FDA Orphan Designations

Approved first, then open designations, newest first
Mar 29, 2019AvaclyrAVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes…Fera PharmaceuticalsApproved
Jun 25, 2025Granzyme B associated peptideTreatment of herpes simplex encephalitis (HSE)BioJENC, LLC.Designated
Jun 24, 2022HSV-1-erasing lentivirus-like particle delivering…Treatment of herpes simplex (HSV-1) infected keratitis (HSK)Hangzhou BDgene Co., Ltd.Designated
May 29, 1990PR-225 (redox-acyclovir)Treatment of herpes simplex encephalitis in individuals afflicted with AIDS.PharmosDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.